Your browser doesn't support javascript.
loading
Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis.
Zhu, Hong; Wang, Dan-Dan; Yuan, Tao; Yan, Fang-Jie; Zeng, Chen-Ming; Dai, Xiao-Yang; Chen, Zi-Bo; Chen, Ying; Zhou, Tianyi; Fan, Guang-Han; Ying, Meidan; Cao, Ji; Luo, Peihua; Liu, Xi-Jie; Hu, Yuandong; Peng, Yong; He, Qiaojun; Yang, Bo.
Afiliação
  • Zhu H; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Wang DD; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Yuan T; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Yan FJ; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Zeng CM; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Dai XY; Center for Drug Safety Evaluation and Research of Zhejiang University, Hangzhou, China.
  • Chen ZB; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Chen Y; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Zhou T; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Fan GH; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Ying M; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Cao J; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Luo P; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Liu XJ; Medicinal Chemistry Department, Centaurus BioPharma Co., Ltd., Beijing, China.
  • Hu Y; Medicinal Chemistry Department, Centaurus BioPharma Co., Ltd., Beijing, China.
  • Peng Y; Discovery Biology Department, Centaurus BioPharma Co., Ltd., Beijing, China.
  • He Q; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. yang924@zju.edu.cn qiaojunhe@zju.edu.cn.
  • Yang B; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. yang924@zju.edu.cn qiaojunhe@zju.edu.cn.
Cancer Res ; 78(14): 3995-4006, 2018 07 15.
Article em En | MEDLINE | ID: mdl-29669759
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Proteínas Nucleares / Receptor IGF Tipo 1 / Inibidores de Proteínas Quinases / Neoplasias Hepáticas / Hipóxia Tipo de estudo: Prognostic_studies Limite: Animals / Humans País/Região como assunto: Asia Idioma: En Revista: Cancer Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Proteínas Nucleares / Receptor IGF Tipo 1 / Inibidores de Proteínas Quinases / Neoplasias Hepáticas / Hipóxia Tipo de estudo: Prognostic_studies Limite: Animals / Humans País/Região como assunto: Asia Idioma: En Revista: Cancer Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China